Compounded Semaglutide at a Med Spa: Office Stock, 503B, Who Injects
A med spa or weight-loss clinic can't legally keep a general supply of compounded semaglutide from an ordinary compounding pharmacy. That kind of pharmacy (a 503A pharmacy) can only fill a prescription written for you by name. The other source, an FDA-registered 503B outsourcing facility, can make office stock. But as of October 2026, semaglutide and tirzepatide are on neither of the two lists a 503B needs to compound them from raw ingredient, and FDA has proposed keeping them off. So before you take an in-office shot, ask exactly where the drug came from, whose name is on it, and who examined you.
Key takeaways
- 503A pharmacies compound for an "identified individual patient" with a valid prescription. A 503A vial should be labeled for you, not stocked for the clinic.
- 503B outsourcing facilities may supply clinics without patient-specific prescriptions, labeled "Office Use Only," but they can use a bulk ingredient only if it is on FDA's clinical-need list or the drug is on the shortage list.
- FDA said on April 1, 2026 that semaglutide and tirzepatide are on neither list. On May 1, 2026, it published a proposal to keep them, and liraglutide, off the 503B bulks list.
- Who may examine you, prescribe, and inject depends on state law. Generally a licensed prescriber must evaluate you first, and any delegated injection happens under supervision.
- Compounded GLP-1s are not FDA-approved. A clinic's license, or a facility's FDA registration, is not approval of the product.
Two legal sources for compounded drugs, and how they differ
503A pharmacies: patient-specific only
Section 503A of the Food, Drug, and Cosmetic Act covers state-licensed pharmacies and physicians. Its exemptions apply to a drug "compounded for an identified individual patient based on the receipt of a valid prescription order" (21 U.S.C. 353a). FDA restated in April 2026 that a 503A compounded drug must be prepared for an individual patient under a prescription (FDA, April 1, 2026).
In practice, a legitimate 503A product given to you at a clinic should come from a prescription in your name, and the label should identify you. 503A pharmacies also face the "essentially a copy" limit: they can't regularly compound copies of commercially available drugs unless a prescriber documents a significant difference for that patient (21 U.S.C. 353a).
503B outsourcing facilities: office stock allowed, with conditions
Section 503B created "outsourcing facilities." These facilities compound sterile drugs, register with FDA, and are "not required to be a licensed pharmacy." The statute says an outsourcing facility "may or may not obtain prescriptions for identified individual patients." That is what makes office stock possible (21 U.S.C. 353b).
The conditions matter. A 503B facility may compound from a bulk drug substance only if that substance is on FDA's list of bulk substances with a clinical need, or if the drug is on FDA's drug shortage list. Labels must say "This is a compounded drug" and "Not for resale." Drugs dispensed without a patient-specific prescription must also say "Office Use Only." The statute adds that the drug "will not be sold or transferred by an entity other than the outsourcing facility" (21 U.S.C. 353b).
| Question | 503A pharmacy | 503B outsourcing facility |
|---|---|---|
| Needs a prescription for each patient? | Yes, for an identified individual patient | No; may or may not obtain one |
| Can supply clinic office stock? | No | Yes, labeled "Office Use Only" |
| Registered with FDA? | No; licensed by the state | Yes; listed on FDA's outsourcing facility page |
| Semaglutide or tirzepatide from bulk ingredient, October 2026? | Subject to essentially-a-copy limits | Not on the bulks list or the shortage list |
| Product FDA-approved? | No | No |
Sources: 21 U.S.C. 353a and 353b; FDA statement updated April 1, 2026.
Where semaglutide and tirzepatide stand for 503B in 2026
FDA's April 1, 2026 statement says that neither tirzepatide nor semaglutide is on the 503B bulks list or the drug shortage list (FDA, April 1, 2026). The same page records that FDA declared the tirzepatide shortage resolved in October 2024, then confirmed that decision in December 2024. It declared the semaglutide shortage resolved on February 21, 2025, and the 503B transition period for semaglutide ended May 22, 2025.
On May 1, 2026, FDA published a Federal Register notice proposing not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list. FDA tentatively found no clinical need to compound them from bulk substances. The notice explains that FDA does not treat supply issues such as backorders, cost compared with an approved drug, or convenience as "clinical need" under its framework (Federal Register, May 1, 2026). The original 60-day comment period was set to close June 30, 2026; FDA later extended it to July 30, 2026 (Federal Register, June 26, 2026). A final determination would be published separately, so check docket FDA-2018-N-3240 for its current status.
The notice also says FDA sees benefits when it is "feasible to compound a drug product by starting with an FDA-approved drug product" instead of bulk ingredient (Federal Register). That is a different situation from a 503B facility making semaglutide from raw API. It is one more reason to ask the clinic for the exact source rather than accept "it's from a 503B."
Compare available care options
If you would rather fill a prescription in your own name, you can compare how participating providers describe their prescribers and pharmacies, then verify those details yourself.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Who can examine you, prescribe, and inject
This part is governed by state medical, nursing, and pharmacy law, and it varies. A general summary from the American Med Spa Association says that a licensed prescriber (a physician, PA, or advanced practice nurse) must establish a relationship with you through a good-faith exam before prescribing. That exam includes a history, a physical assessment, and appropriate tests. After that, the injection can usually be delegated to trained staff under the prescriber's supervision. Some states limit administration to licensed nurses, while others allow medical assistants (AmSpa, 2023).
One state example shows how specific the rules can get:
- Florida. Board of Medicine Rule 64B8-9.012, "Standards for the Prescription of Drugs to Treat Obesity," was last amended August 8, 2022 (Florida Administrative Code). The rule sets Florida-specific standards for prescribing weight-loss drugs, and the Board of Medicine has handled variance and waiver petitions under it, including from a telehealth weight-loss company. Its full text is linked from the Florida Administrative Code page; read it, or ask the clinic how it complies, rather than relying on a summary.
Your state may differ. Your state medical board and board of nursing can tell you who may do what. Both also let you look up whether a license is active.
Decision table: what the clinic tells you
| What you hear | What it should mean | Follow-up question |
|---|---|---|
| "It's from a compounding pharmacy." | If 503A, a prescription in your name and a label with your name | Which pharmacy, and may I see the label with my name on it? |
| "We buy it from a 503B." | A named facility on FDA's registered list; "Office Use Only" labeling | Which facility? Is it compounding from bulk API or from an approved product? |
| "It's research-grade" or "for research use" | Not a lawful pharmacy product; FDA urges consumers not to use these | Decline. |
| "The nurse will decide your dose." | Dosing should come from a prescriber's order after an evaluation | Who is the prescriber, and when did they evaluate me? |
| "It's semaglutide sodium" or another salt form | FDA knows of no lawful basis for compounding with salt forms | Decline, and ask what the prescriber recommends instead. |
Sources: 21 U.S.C. 353a and 353b; FDA, "FDA's concerns with unapproved GLP-1 drugs used for weight loss" (updated October 1, 2026).
FDA has warned that products labeled "for research purposes" or "not for human consumption" are being sold to consumers with dosing instructions, and urges people not to buy them. It also says semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs (FDA).
Six checks before an in-office GLP-1 shot
- Name the source. Get the pharmacy or outsourcing facility's name and whether it is 503A or 503B.
- Look it up. For a 503B, find it on FDA's registered outsourcing facility list. The list shows last inspection, whether a Form 483 was issued, recalls, and actions such as warning letters (FDA). For a 503A, check the state board of pharmacy license.
- See the vial. Ask to see the label: the drug and its form, concentration, lot number, beyond-use date, and either your name (503A) or "Office Use Only" (503B).
- Confirm the evaluation. Who examined you, what is their license, and who wrote the order for your dose?
- Confirm who injects and who supervises. Ask for the person's credential and whether the supervising prescriber is on-site or reachable.
- Ask about alternatives. Ask whether the clinic offers a prescription you can fill elsewhere, including for an FDA-approved product.
A worked example (hypothetical)
This is an illustration, not a real clinic. A reader is offered walk-in "semaglutide shots, no appointment with the doctor needed." Staff say the drug comes "from a 503B." The vial in the fridge says "Office Use Only" with a facility name the reader can't find on FDA's list.
Three things don't line up. A facility not on FDA's list isn't a registered 503B. FDA says semaglutide isn't on the 503B bulks list or the shortage list. And skipping a prescriber evaluation conflicts with the general good-faith exam requirement. The reader doesn't need to settle the legal question. Declining and asking for a prescriber visit, or a prescription to fill at a pharmacy, is a reasonable response.
Where this guide stops
This guide can't confirm whether a particular clinic or facility is compliant. Only regulators can make that call. State rules on med spas, delegation, and medical director requirements change often and differ widely. The state example is an illustration, not a survey. FDA's 503B bulks decision was still a proposal in the documents reviewed here. Whether a GLP-1 is right for you, and which one, is a decision for a licensed prescriber who has evaluated you.
Compare available care options
Listings show participating providers' stated prescribers, pharmacies, and terms; verify credentials yourself, and remember a listing is not a recommendation or a prescription.
Paid links. We may earn a commission; it never changes what we write. See all options. Compounded medications are not FDA-approved.
Disclosure: this site may earn a commission if you use a listed provider. Compensation does not establish a product's safety, legality, or value.
Frequently asked questions
Can a med spa keep compounded semaglutide in stock?
Not from a 503A pharmacy, which may compound only for an identified individual patient with a prescription. A registered 503B outsourcing facility can supply office stock labeled 'Office Use Only,' but FDA says semaglutide and tirzepatide are on neither the 503B bulks list nor the drug shortage list.
What did FDA propose for semaglutide and tirzepatide under 503B in 2026?
In a Federal Register notice published May 1, 2026, FDA proposed not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list, tentatively finding no clinical need. The comment period was extended to July 30, 2026; a final determination would be published separately.
Who is allowed to give me a GLP-1 injection at a clinic?
It depends on state law. Generally a licensed prescriber must evaluate you first, and the injection may be delegated to trained staff under supervision; some states limit administration to licensed nurses.
How can I check a clinic's 503B supplier?
Ask for the facility's name and look it up on FDA's Registered Outsourcing Facilities page, which shows registration dates, last inspection, Form 483s, recalls, and actions such as warning letters.
Sources
- 21 U.S.C. 353a (FD&C Act section 503A), Cornell LII
- 21 U.S.C. 353b (FD&C Act section 503B), Cornell LII
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026)
- Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (May 1, 2026)
- Federal Register: Extension of Comment Period (June 26, 2026)
- FDA: Registered Outsourcing Facilities
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
- American Med Spa Association: Who Can Perform Semaglutide Treatments? (2023)
- Florida Administrative Code Rule 64B8-9.012
Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.